Abivax 更新了溃疡性结肠炎的联合治疗策略，提供了 Obefazimod 和 Etrasimod 的有希望的临床前数据。 Abivax updates combination therapy strategy for ulcerative colitis with promising preclinical data on Obefazimod and Etrasimod.

Abivax 更新了针对溃疡性结肠炎 （UC） 的联合治疗计划策略。 Abivax has updated its strategy for a combination therapy program targeting ulcerative colitis (UC). 该公司以发炎性肠道疾病(IBD)的鼠标模型宣布了早期临床预科数据,表明其药物(Obefazimod和Etrasimod)的效力。 The company announced early preclinical data demonstrating the effectiveness of its drugs, Obefazimod and Etrasimod, in a mouse model of inflammatory bowel disease (IBD). 这项研究旨在推进对患UCU症病人的治疗选择。 This research aims to advance treatment options for patients with UC.